中国防痨杂志 ›› 2022, Vol. 44 ›› Issue (9): 954-959.doi: 10.19982/j.issn.1000-6621.20220243
收稿日期:
2022-06-27
出版日期:
2022-09-10
发布日期:
2022-09-05
通信作者:
王庆文
E-mail:wqw_sw@163.com
基金资助:
Wu Wenqi1, Zhong Jianqiu1, He Juan1, Deng Guofang2, Wang Qingwen1()
Received:
2022-06-27
Online:
2022-09-10
Published:
2022-09-05
Contact:
Wang Qingwen
E-mail:wqw_sw@163.com
Supported by:
摘要:
风湿性疾病是一组自身免疫与炎症性疾病,其主要特征是免疫系统的紊乱。同时,随着各种免疫抑制剂、生物制剂在风湿性疾病中的应用,机体的免疫状态大大改变,从而使结核分枝杆菌潜伏感染激活的风险增加。为更好地了解风湿性疾病患者结核分枝杆菌潜伏感染激活的机制,以期进一步降低结核病的发生率和患者病亡率,笔者从结核感染的免疫反应机制、风湿性疾病患者结核分枝杆菌潜伏感染激活的机制、增加结核分枝杆菌潜伏感染激活风险的治疗药物等方面进行综述,以供参考。
中图分类号:
吴文琪, 钟剑球, 何娟, 邓国防, 王庆文. 风湿性疾病患者结核分枝杆菌潜伏感染激活机制的研究进展[J]. 中国防痨杂志, 2022, 44(9): 954-959. doi: 10.19982/j.issn.1000-6621.20220243
Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959. doi: 10.19982/j.issn.1000-6621.20220243
[1] |
Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther, 2008, 10(1):R17. doi: 10.1186/ar2368.
doi: 10.1186/ar2368 URL |
[2] |
da Silva MA, Martins A, Teixeira AA, et al. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases. Tissue Eng Part B Rev, 2010, 16(3):331-339. doi: 10.1089/ten.TEB.2009.0536.
doi: 10.1089/ten.TEB.2009.0536 URL |
[3] |
Scriba TJ, Coussens AK, Fletcher HA. Human Immunology of Tuberculosis. Microbiol Spectr, 2017, 5(1). doi: 10.1128/microbiolspec.TBTB2-0016-2016.
doi: 10.1128/microbiolspec.TBTB2-0016-2016 |
[4] |
Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol, 2012, 7:353-384. doi: 10.1146/annurev-pathol-011811-132458.
doi: 10.1146/annurev-pathol-011811-132458 URL |
[5] | World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021. |
[6] | Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000, 49(RR-6):1-51. |
[7] |
Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis[J/OL]. Lancet Respir Med, 2017[2022-06-23]. doi: 10.1016/S2213-2600(17)30079-6. Online ahead of print.
doi: 10.1016/S2213-2600(17)30079-6 |
[8] |
Cantini F, Nannini C, Niccoli L, et al. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm, 2017, 2017: 8909834. doi: 10.1155/2017/8909834.
doi: 10.1155/2017/8909834 |
[9] |
Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4):10.1128/microbiolspec.GPP3-0022-2018. doi: 10.1128/microbiolspec.GPP3-0022-2018.
doi: 10.1128/microbiolspec.GPP3-0022-2018 URL |
[10] |
Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest, 2010, 137(1):122-128. doi: 10.1378/chest.09-0903.
doi: 10.1378/chest.09-0903 URL |
[11] |
Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol, 2009, 11(8):1170-1178. doi: 10.1111/j.1462-5822.2009.01335.x.
doi: 10.1111/j.1462-5822.2009.01335.x. URL |
[12] |
Chen M, Gan H, Remold HG. A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol, 2006, 176(6):3707-3716. doi: 10.4049/jimmunol.176.6.3707.
doi: 10.4049/jimmunol.176.6.3707 URL |
[13] |
Wolf AJ, Linas B, Trevejo-Nuñez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol, 2007, 179(4):2509-2519. doi: 10.4049/jimmunol.179.4.2509.
doi: 10.4049/jimmunol.179.4.2509 URL |
[14] |
Chan WL, Rodgers A, Hancock RD, et al. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class Ⅰ antibody response. J Exp Med, 1992, 176(4):1203-1207. doi: 10.1084/jem.176.4.1203.
doi: 10.1084/jem.176.4.1203 pmid: 1402662 |
[15] |
Goletti D, Petruccioli E, Romagnoli A, et al. Autophagy in Mycobacterium tuberculosis infection: a passepartout to flush the intruder out? Cytokine Growth Factor Rev, 2013, 24(4):335-343. doi: 10.1016/j.cytogfr.2013.01.002.
doi: 10.1016/j.cytogfr.2013.01.002 URL |
[16] |
Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science, 1997, 276(5319):1684-1687. doi: 10.1126/science.276.5319.1684.
doi: 10.1126/science.276.5319.1684 pmid: 9180075 |
[17] |
Ernst WA, Thoma-Uszynski S, Teitelbaum R, et al. Granuly-sin, a T cell product, kills bacteria by altering membrane permeability. J Immunol, 2000, 165(12):7102-7108. doi: 10.4049/jimmunol.165.12.7102.
doi: 10.4049/jimmunol.165.12.7102 pmid: 11120840 |
[18] |
Loxton AG. Bcells and their regulatory functions during Tuberculosis: Latency and active disease. Mol Immunol, 2019, 111:145-151. doi: 10.1016/j.molimm.2019.04.012.
doi: S0161-5890(18)30870-8 pmid: 31054408 |
[19] |
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol, 2010, 28:445-489. doi: 10.1146/annurev-immunol-030409-101212.
doi: 10.1146/annurev-immunol-030409-101212 URL |
[20] |
van Rensburg IC, Wagman C, Stanley K, et al. Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA. Oncotarget, 2017, 8(2): 2037-2043. doi: 10.18632/oncotarget.12184.
doi: 10.18632/oncotarget.12184 pmid: 27682872 |
[21] |
du Plessis WJ, Kleynhans L, du Plessis N, et al. The Functional Response of B Cells to Antigenic Stimulation: A Preli-minary Report of Latent Tuberculosis. PLoS One, 2016, 11(4):e0152710. doi: 10.1371/journal.pone.0152710.
doi: 10.1371/journal.pone.0152710 URL |
[22] |
Khan N, Vidyarthi A, Amir M, et al. T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol, 2017, 43(2):133-141. doi: 10.1080/1040841X.2016.1185603.
doi: 10.1080/1040841X.2016.1185603 URL |
[23] |
Foreman TW, Mehra S, LoBato DN, et al. CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. Proc Natl Acad Sci U S A, 2016, 113(38):E5636-E5644. doi: 10.1073/pnas.1611987113.
doi: 10.1073/pnas.1611987113 |
[24] |
Sutherland JS, Lalor MK, Black GF, et al. Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. PLoS One, 2013, 8(9):e74080. doi: 10.1371/journal.pone.0074080.
doi: 10.1371/journal.pone.0074080 URL |
[25] |
Riaño F, Arroyo L, París S, et al. T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis (Edinb), 2012, 92(2):148-159. doi: 10.1016/j.tube.2011.12.005.
doi: 10.1016/j.tube.2011.12.005 URL |
[26] |
Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol, 2021, 22(1):10-18. doi: 10.1038/s41590-020-00816-x.
doi: 10.1038/s41590-020-00816-x URL |
[27] |
Blank CU, Haining WN, Held W, et al. Defining ’T cell exhaustion’. Nat Rev Immunol, 2019, 19(11):665-674. doi: 10.1038/s41577-019-0221-9.
doi: 10.1038/s41577-019-0221-9 URL |
[28] |
Frenz T, Grabski E, Buschjäger D, et al. CD4+ T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin Immunol, 2016, 138(2):586-589.e10. doi: 10.1016/j.jaci.2016.04.013.
doi: 10.1016/j.jaci.2016.04.013 URL |
[29] |
Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995, 3(5):541-547. doi: 10.1016/1074-7613(95)90125-6.
doi: 10.1016/1074-7613(95)90125-6 pmid: 7584144 |
[30] |
Waterhouse P, Penninger JM, Timms E, et al. Lymphopro-liferative disorders with early lethality in mice deficient in Ctla-4. Science, 1995, 270(5238):985-988. doi: 10.1126/science.270.5238.985.
doi: 10.1126/science.270.5238.985 pmid: 7481803 |
[31] |
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322(5899):271-275. doi: 10.1126/science.1160062.
doi: 10.1126/science.1160062 URL |
[32] | 先声药业集团有限公司. 阿巴西普药物说明书[EB/OL].[2022-06-23]. https://packageinserts.bms.com/pi/pi_orencia.pdf. |
[33] |
Tang S, Cui H, Yao L, et al. Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease. PLoS One, 2013, 8(4):e62385. doi: 10.1371/journal.pone.0062385.
doi: 10.1371/journal.pone.0062385 URL |
[34] |
Kumar NP, Moideen K, Banurekha VV, et al. Plasma Proinflammatory Cytokines Are Markers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. Open Forum Infect Dis, 2019, 6(7):ofz257. doi: 10.1093/ofid/ofz257.
doi: 10.1093/ofid/ofz257 URL |
[35] |
Lyadova IV, Panteleev AV. Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers. Mediators Inflamm, 2015, 2015: 854507. doi: 10.1155/2015/854507.
doi: 10.1155/2015/854507 |
[36] |
Herrera M, Vera C, Keynan Y, et al. Gaps in Study Design for Immune Parameter Research for Latent Tuberculosis Infection: A Systematic Review. J Immunol Res, 2020, 2020:8074183. doi: 10.1155/2020/8074183.
doi: 10.1155/2020/8074183 |
[37] |
Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 2003, 3(3):148-155. doi: 10.1016/s1473-3099(03)00545-0.
doi: 10.1016/s1473-3099(03)00545-0 URL |
[38] |
Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol, 2006, 2(11):602-610. doi: 10.1038/ncprheum0336.
doi: 10.1038/ncprheum0336 pmid: 17075599 |
[39] |
Kaneko H, Yamada H, Mizuno S, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest, 1999, 79(4):379-386.
pmid: 10211990 |
[40] |
Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest, 2009, 119(5):1167-1177. doi: 10.1172/JCI38482.
doi: 10.1172/JCI38482 URL |
[41] |
Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis-time for a paradigm change. J Eur Acad Dermatol Venereol, 2021, 35(4):824-834. doi: 10.1111/jdv.16866.
doi: 10.1111/jdv.16866 URL |
[42] |
Skattum L, van Deuren M, van der Poll T, et al. Complement deficiency states and associated infections. Mol Immunol, 2011, 48(14):1643-1655. doi: 10.1016/j.molimm.2011.05.001.
doi: 10.1016/j.molimm.2011.05.001 URL |
[43] |
Esmail H, Lai RP, Lesosky M, et al. Complement pathway gene activation and rising circulating immune complexes charac-terize early disease in HIV-associated tuberculosis. Proc Natl Acad Sci U S A, 2018, 115(5):E964-E973. doi: 10.1073/pnas.1711853115.
doi: 10.1073/pnas.1711853115 |
[44] |
Schlesinger LS. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol, 1993, 150(7):2920-2930.
pmid: 8454864 |
[45] |
Jagatia H, Tsolaki AG. The Role of Complement System and the Immune Response to Tuberculosis Infection. Medicina (Kaunas), 2021, 57(2):84. doi: 10.3390/medicina57020084.
doi: 10.3390/medicina57020084 |
[46] |
Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol, 2003, 15(5):528-534. doi: 10.1097/00002281-200309000-00002.
doi: 10.1097/00002281-200309000-00002 URL |
[47] |
Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis, 2008, 46(3):443-446. doi: 10.1086/525268.
doi: 10.1086/525268 URL |
[48] |
Realegeno S, Modlin RL. Shedding light on the vitamin D-tuberculosis-HIV connection. Proc Natl Acad Sci U S A, 2011, 108(47):18861-18862. doi: 10.1073/pnas.1116513108.
doi: 10.1073/pnas.1116513108 pmid: 22084116 |
[49] |
Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768):1770-1773. doi: 10.1126/science.1123933.
doi: 10.1126/science.1123933 URL |
[50] |
Adams JS, Ren S, Liu PT, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol, 2009, 182(7):4289-4295. doi: 10.4049/jimmunol.0803736.
doi: 10.4049/jimmunol.0803736 pmid: 19299728 |
[51] |
Raqib R, Ly A, Akhtar E, et al. Prenatal vitamin D supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity. Br J Nutr, 2014, 112(6):908-915. doi: 10.1017/S0007114514001512.
doi: 10.1017/S0007114514001512 URL |
[52] |
Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med, 2007, 176(2):208-213. doi: 10.1164/rccm.200701-007OC.
doi: 10.1164/rccm.200701-007OC URL |
[53] |
Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med, 2007, 176(2):208-213. doi: 10.1164/rccm.200701-007OC.
doi: 10.1164/rccm.200701-007OC URL |
[54] |
Nguyen Y, Sigaux J, Letarouilly JG, et al. Efficacy of Oral Vitamin Supplementation in Inflammatory Rheumatic Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2020, 13(1):107. doi: 10.3390/nu13010107.
doi: 10.3390/nu13010107 URL |
[55] |
Zheng R, Gonzalez A, Yue J, et al. Efficacy and Safety of Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus: A Meta-analysis of Randomized Controlled Trials. Am J Med Sci, 2019, 358(2):104-114. doi: 10.1016/j.amjms.2019.04.020.
doi: 10.1016/j.amjms.2019.04.020 URL |
[56] |
Diao N, Yang B, Yu F. Effect of vitamin D supplementation on knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. Clin Biochem, 2017, 50(18):1312-1316. doi: 10.1016/j.clinbiochem.2017.09.001.
doi: 10.1016/j.clinbiochem.2017.09.001 URL |
[57] |
Carvalho JF, Blank M, Kiss E, et al. Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci, 2007, 1109:550-557. doi: 10.1196/annals.1398.061.
doi: 10.1196/annals.1398.061 URL |
[58] |
Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum, 2009, 61(3):300-304. doi: 10.1002/art.24476.
doi: 10.1002/art.24476 URL |
[59] |
Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum, 2006, 55(1):19-26. doi: 10.1002/art.21705.
doi: 10.1002/art.21705 URL |
[60] |
Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med, 1973, 137(4):1031-1041. doi: 10.1084/jem.137.4.1031.
doi: 10.1084/jem.137.4.1031 pmid: 4693151 |
[61] |
Rinehart JJ, Sagone AL, Balcerzak SP, et al. Effects of corticosteroid therapy on human monocyte function. N Engl J Med, 1975, 292(5):236-241. doi: 10.1056/NEJM19750130 2920504.
doi: 10.1056/NEJM19750130 2920504 URL |
[62] |
Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med, 1976, 84(3):304-315. doi: 10.7326/0003-4819-84-3-304.
doi: 10.7326/0003-4819-84-3-304 pmid: 769625 |
[63] |
Ai JW, Zhang S, Ruan QL, et al. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. J Rheumatol, 2015, 42(12):2229-2237. doi: 10.3899/jrheum.150057.
doi: 10.3899/jrheum.150057 URL |
[64] |
Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis, 2000, 59(11):841-849. doi: 10.1136/ard.59.11.841.
doi: 10.1136/ard.59.11.841 pmid: 11053058 |
[65] |
Miceli-Richard C, Dougados M. Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother, 2003, 4(6):987-997. doi: 10.1517/14656566.4.6.987.
doi: 10.1517/14656566.4.6.987 URL |
[66] | Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis, 2007, 65(3):168-173. |
[67] |
Hong W, Wang Y, Chang Z, et al. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling. Sci Rep, 2015, 5:15328. doi: 10.1038/srep15328.
doi: 10.1038/srep15328 pmid: 26471125 |
[68] |
Leitner J, Drobits K, Pickl WF, et al. The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett, 2011, 140(1/2):74-80. doi: 10.1016/j.imlet.2011.06.010.
doi: 10.1016/j.imlet.2011.06.010 URL |
[69] |
Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol, 2018, 14(9):719-730. doi: 10.1080/1744666X.2018.1512404.
doi: 10.1080/1744666X.2018.1512404 URL |
[70] |
Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis, 2017, 76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457.
doi: 10.1136/annrheumdis-2016-210457 URL |
[71] | 美国辉瑞制药有限公司. 枸橼酸托法替布片说明书[EB/OL]. [2022-06-23]. https://labeling.pfizer.com/ShowLabeling.aspx?id=14493. |
[1] | 邓国防, 王庆文. 重视风湿性疾病合并结核感染的多学科诊治[J]. 中国防痨杂志, 2022, 44(9): 865-868. |
[2] | 国家感染性疾病临床医学研究中心/深圳市第三人民医院, 北京大学深圳医院, 中国医学科学院北京协和医院, 中国防痨协会, 《中国防痨杂志》编辑委员会, 深圳市炎症与免疫性疾病重点实验室. 风湿性疾病患者合并结核分枝杆菌潜伏感染诊治的专家共识[J]. 中国防痨杂志, 2022, 44(9): 869-879. |
[3] | 王玉香, 陈秋奇, 余鑫鑫, 詹森林, 张培泽, 邓国防. 3HP方案治疗风湿性疾病合并结核分枝杆菌潜伏感染的前瞻性研究[J]. 中国防痨杂志, 2022, 44(9): 906-910. |
[4] | 陈秋奇, 韩婷婷, 王庆文, 邓国防. 风湿性疾病合并结核分枝杆菌潜伏感染的诊治进展[J]. 中国防痨杂志, 2022, 44(9): 960-965. |
[5] | 姚蓉, 陆宇. 抗结核药物贝达喹啉的耐药情况及其耐药机制研究进展[J]. 中国防痨杂志, 2022, 44(9): 973-977. |
[6] | 谢芳晖, 梁丽, 赵霞, 姚蓉, 雷丽梅, 郭慧, 孟萌, 万彬. 肺结核患者痰标本采集的研究进展[J]. 中国防痨杂志, 2022, 44(9): 978-982. |
[7] | 成君, 高磊. 结核分枝杆菌感染检测在学校人群中的应用[J]. 中国防痨杂志, 2022, 44(8): 757-761. |
[8] | 成君, 陆伟. 《基层医疗卫生机构结核感染预防与控制指南》解读[J]. 中国防痨杂志, 2022, 44(8): 762-767. |
[9] | 祝平, 郝晓刚, 王炜, 陈彬. 浙江省衢州市高疫情农村老年人非活动性肺结核流行特征分析[J]. 中国防痨杂志, 2022, 44(8): 815-820. |
[10] | 丁秀荣, 刘家琛, 陈淑华, 康艳芳, 王晨, 娄金丽. 艾滋病患者合并分枝杆菌血流感染的临床特征分析[J]. 中国防痨杂志, 2022, 44(8): 821-826. |
[11] | 刘晓童, 王安素, 蒋中艳, 娄义姣, 高奉琼, 冯加义, 夏同霞. 结核病患者营养筛查和评估工具研究进展[J]. 中国防痨杂志, 2022, 44(8): 855-859. |
[12] | 贾红彦, 董静, 张宗德, 潘丽萍. 结核分枝杆菌感染的免疫学检测技术研究进展及临床应用现状[J]. 中国防痨杂志, 2022, 44(7): 720-726. |
[13] | 何翼君, 曹雪芳, 高磊. 《结核菌素皮肤试验-γ干扰素释放试验两步法的操作技术规范》解读[J]. 中国防痨杂志, 2022, 44(5): 438-441. |
[14] | 熊姿, 谢赐福, 宋丽新, 王孝君, 田斌, 黄竹林, 徐祖辉, 张锡兴, 白丽琼. 2011—2020年长沙市MTB/HIV双重感染流行特征分析[J]. 中国防痨杂志, 2022, 44(5): 484-488. |
[15] | 李玉洁, 杨雨婷, 杨国平. 糖尿病合并结核感染的固有免疫和适应性免疫反应的研究进展[J]. 中国防痨杂志, 2022, 44(5): 512-516. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||